Literature DB >> 11997434

Paracardial lipodystrophy versus pericardial effusion in HIV positive patients.

T Neumann1, A Chanbay, J Barkhausen, T Bartel.   

Abstract

OBJECTIVE: To present an epicardial manifestation of the lipodystrophy syndrome, a side effect of antiretroviral treatment in HIV positive patients, which illustrates the important danger of false diagnosis. PATIENT: A 52 year old man with HIV (stage C3), diagnosed 10 years previously, was being treated with a combination of nelfinavir, nevirapine, and stavudine. Echocardiographic examination showed a low echogenic pericardial space that had increased from 4 mm to 18 mm over a 10 month period. The diagnosis of paracardial adipose tissue was verified by magnetic resonance tomography. Doppler echocardiographic parameters were not significantly altered (ratio of early to late ventricular filling 0.88 v 0.73, Tei index 0.30 v 0.36).
CONCLUSION: Even a pericardial manifestation of lipodystrophy causes negligible functional impairment, misinterpretation of the lipodystrophy as a pericardial effusion and a subsequent puncture can have serious complications. Hence, it is strongly suggested that further differential diagnosis be used for HIV positive patients with an echocardiographic suspicion of pericardial effusion. Differential diagnosis by magnetic resonance tomography is possible.

Entities:  

Mesh:

Year:  2002        PMID: 11997434      PMCID: PMC1767115          DOI: 10.1136/heart.87.5.e4

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  10 in total

1.  Fat distribution in AIDS.

Authors:  V Teplitsky; A Halabe
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

2.  Large pericardial effusions in the acquired immunodeficiency syndrome.

Authors:  M M Reynolds; S R Hecht; M Berger; A Kolokathis; S F Horowitz
Journal:  Chest       Date:  1992-12       Impact factor: 9.410

Review 3.  Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment.

Authors:  S R Penzak; S K Chuck
Journal:  Scand J Infect Dis       Date:  2000

Review 4.  Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

Authors:  A Carr; K Samaras; D J Chisholm; D A Cooper
Journal:  Lancet       Date:  1998-06-20       Impact factor: 79.321

5.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

6.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

Review 7.  Human immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the literature.

Authors:  Y Chen; D Brennessel; J Walters; M Johnson; F Rosner; M Raza
Journal:  Am Heart J       Date:  1999-03       Impact factor: 4.749

8.  Prognostic value of echocardiography in hospitalized patients with pericardial effusion.

Authors:  M J Eisenberg; K Oken; S Guerrero; M A Saniei; N B Schiller
Journal:  Am J Cardiol       Date:  1992-10-01       Impact factor: 2.778

9.  Myocardial contrast echocardiography: a reproducible technique of myocardial opacification for identifying regional perfusion deficits.

Authors:  C Tei; T Sakamaki; P M Shah; S Meerbaum; K Shimoura; S Kondo; E Corday
Journal:  Circulation       Date:  1983-03       Impact factor: 29.690

10.  Pericardial disease and human immunodeficiency virus in Dar es Salaam, Tanzania.

Authors:  J P Cegielski; K Ramiya; G J Lallinger; I A Mtulia; I M Mbaga
Journal:  Lancet       Date:  1990-01-27       Impact factor: 79.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.